share_log

Prime Medicine Analyst Ratings

Prime Medicine Analyst Ratings

Prime 医学分析师评级
Benzinga ·  2023/09/06 04:49
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/06/2023 66.67% JonesTrading → $20 Initiates Coverage On → Buy
08/14/2023 58.33% Morgan Stanley $21 → $19 Maintains Equal-Weight
07/31/2023 100% Guggenheim → $24 Initiates Coverage On → Buy
04/18/2023 50% Stifel → $18 Initiates Coverage On → Buy
01/24/2023 75% Morgan Stanley $23 → $21 Maintains Equal-Weight
11/14/2022 125% JP Morgan → $27 Initiates Coverage On → Overweight
11/14/2022 108.33% Jefferies → $25 Initiates Coverage On → Buy
11/14/2022 91.67% Morgan Stanley → $23 Initiates Coverage On → Equal-Weight
11/14/2022 83.33% Goldman Sachs → $22 Initiates Coverage On → Neutral
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
09/06/2023 66.67% Jones Trading →$20 开始承保 →购买
2023年08月14日 58.33% 摩根士丹利 $21→$19 维护 等重
07/31/2023 100% 古根海姆 →$24 开始承保 →购买
04/18/2023 50% Stifel →$18 开始承保 →购买
01/24/2023 75% 摩根士丹利 $23→$21 维护 等重
2022年11月14日 百分之一百二十五 摩根大通 →$27 开始承保 →超重
2022年11月14日 108.33% 杰富瑞 →$25 开始承保 →购买
2022年11月14日 91.67% 摩根士丹利 →$23 开始承保 →等重
2022年11月14日 83.33% 高盛 →$22 开始承保 →中性

What is the target price for Prime Medicine (PRME)?

Prime Medicine(PRME)的目标价格是多少？

The latest price target for Prime Medicine (NASDAQ: PRME) was reported by JonesTrading on September 6, 2023. The analyst firm set a price target for $20.00 expecting PRME to rise to within 12 months (a possible 66.67% upside). 9 analyst firms have reported ratings in the last year.

琼斯交易公司于2023年9月6日报道了Prime Medicine(纳斯达克代码：PRME)的最新目标价。这家分析公司将目标价定为20.00美元，预计PRME将在12个月内上涨(可能上涨66.67%)。去年有9家分析公司公布了评级。

What is the most recent analyst rating for Prime Medicine (PRME)?

最新分析师对Prime Medicine(PRME)的评级是多少？

The latest analyst rating for Prime Medicine (NASDAQ: PRME) was provided by JonesTrading, and Prime Medicine initiated their buy rating.

优质医药(纳斯达克代码：PRME)的最新分析师评级是由琼斯交易公司提供的，优质医药启动了他们的买入评级。

When is the next analyst rating going to be posted or updated for Prime Medicine (PRME)?

Prime Medicine(PRME)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prime Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prime Medicine was filed on September 6, 2023 so you should expect the next rating to be made available sometime around September 6, 2024.

分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Prime Medicine的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Prime Medicine的上一次评级是在2023年9月6日提交的，所以你应该预计下一次评级将在2024年9月6日左右提供。

Is the Analyst Rating Prime Medicine (PRME) correct?

分析师对Prime Medicine(PRME)的评级正确吗？

While ratings are subjective and will change, the latest Prime Medicine (PRME) rating was a initiated with a price target of $0.00 to $20.00. The current price Prime Medicine (PRME) is trading at is $12.00, which is within the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的Prime Medicine(PRME)评级是以0.00美元至20.00美元的目标价启动的。Prime Medicine(PRME)目前的交易价格为12.00美元，在分析师的预测范围内。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发